Company profile for AcuraStem

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

AcuraStem is a California-based biotechnology company employing cutting-edge technology in its efforts to find treatments and cures for neurodegenerative diseases (NDDs). AcuraStem’s team of PhDs, professors, tech entrepreneurs, and successful drug company veterans are employing the latest scientific breakthroughs to address the most challenging, but we believe tractable, health problems of our time, including amyotrophic la...
AcuraStem is a California-based biotechnology company employing cutting-edge technology in its efforts to find treatments and cures for neurodegenerative diseases (NDDs). AcuraStem’s team of PhDs, professors, tech entrepreneurs, and successful drug company veterans are employing the latest scientific breakthroughs to address the most challenging, but we believe tractable, health problems of our time, including amyotrophic lateral sclerosis (ALS). Our best-in-class technology platform consists of complex cellular models from ALS patient cells and sophisticated assays which permit AcuraStem’s scientists to model patient tissues

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
605 E. Huntington Dr., Suite 103 Monrovia, CA 91016-6352
Telephone
Telephone
(213) 290-0635
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/acurastem-welcomes-dr-marcel-van-der-brug-as-chief-scientific-officer-302323134.html

PR NEWSWIRE
05 Dec 2024

https://www.prnewswire.com/news-releases/acurastem-enters-into-a-license-agreement-with-takeda-to-advance-pikfyve-therapeutics-301937595.html

PR NEWSWIRE
26 Sep 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty